Comparison · NCT02246439-2fe84e25
RHB-102 vs Placebo Oral Tablet: Number of Patients Receiving Rescue Antiemetic Therapy - ITT Population
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. RHB-102 vs Placebo Oral Tablet: Number of Patients Receiving Rescue Antiemetic Therapy - ITT Population. Trial comparisons, record NCT02246439-2fe84e25. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02246439-2fe84e25
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.25 | 0.194 | 0.316 | wilson | |
| Risk in group 2 | 0.333 | 0.258 | 0.418 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0833 | -0.185 | 0.0168 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.75 | 0.531 | 1.06 | log | |
| Odds ratio, group 1 over group 2 | 0.667 | 0.408 | 1.09 | log | |
| Number needed to treat, for one fewer participant with the outcome on RHB-102 than on Placebo Oral Tablet | 12 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | RHB-102 | 1 tablet containing 6 mg immediate release and 18 mg sustained release ondansetron, once daily for up to 4 days. | 48 | 192 | OG000 |
| Group 2 | Placebo Oral Tablet | 1 tablet of matching placebo, once daily for up to 4 days. | 43 | 129 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients Receiving Rescue Antiemetic Therapy - ITT Population
- Description
- Patients receiving rescue antiemetic therapy within 24 hours after the first dose of study medication.
- Time frame
- 24 Hours
- Population
- The Intent-to-treat (ITT) Population consisted of all patients who received any study medication, even if they vomited shortly after administration or were unable to swallow the medication.
Source ClinicalTrials.gov
Trial
- Title
- BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
- NCT number
- NCT02246439
- Phases
- PHASE3
- Conditions
- Gastroenteritis, Gastritis
- Interventions
- RHB-102, Placebo Oral Tablet
- Lead sponsor
- RedHill Biopharma Limited
- Results first posted
- 2019-02-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02246439?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02246439-2fe84e25